Loading...
To compare the strengths of three approaches for deciding which primary-prevention patients should be treated with a statin, investigators analyzed data from the Copenhagen General Population Study on 37,892 subjects enrolled in 2003–2008 and free of atherosclerotic cardiovascular disease (ASCVD), diabetes, and statin use at baseline (age range, 40–75; mean age, 56; 57% women).
The three approaches to determine eligibility for a primary-prevention statin were:
Risk-based, per the 2013 cholesterol guidelines from the American College of Cardiology/American Heart Association (ACC/AHA; NEJM JW Cardiol Jan 2014 and J Am Coll Cardiol 2014; 63:2889); patients aged 40 to 75 with 10-year ASCVD risk ≥7.5% or LDL-cholesterol ≥190 mg/dL were eligible.
Tr…